Stock Events

TransCode Therapeutics 

$0.72
48
+$0.01+1.81% Friday 21:00

Statistics

Day High
0.74
Day Low
0.7
52W High
392
52W Low
0.56
Volume
318,796
Avg. Volume
691,893
Mkt Cap
451,757
P/E Ratio
0
Dividend Yield
-
Dividend
-

Earnings

30MarExpected
Q2 2021
Q3 2021
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q4 2022
-0.4
-0.1
0.21
0.51
Expected EPS
-0.38
Actual EPS
0

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RNAZ. It's not an investment recommendation.

Analyst Ratings

3$Average Price Target
The highest estimate is $3.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

About

TransCode Therapeutics, Inc., a biopharmaceutical company, engages in the development and commercialization of drugs and diagnostics for treating and identifying metastatic disease. Its lead therapeutic candidate, TTX-MC138, is a preclinical stage product for the treatment of metastatic cancer. The company's products in preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B. Its cancer agnostic programs comprise TTX-RIGA, an RNA–based agonist of the RIG-I-driven immune response in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9–based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines meant to activate cytotoxic immune responses against tumor cells. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Show more...
CEO
Employees
19
Country
US
ISIN
US89357L1052

Listings